Igor Bilinsky
Chief Operating Officer en IOVANCE BIOTHERAPEUTICS, INC. .
Fortuna: 582 958 $ al 29/02/2024
Perfil
Igor P. Bilinsky ocupa el cargo de Director de Operaciones de Iovance Biotherapeutics, Inc. Anteriormente, el Dr. Bilinsky ocupó el cargo de Director General de Androclus Therapeutics, Inc., Vicepresidente de Desarrollo Comercial y Operaciones Especiales de Halozyme Therapeutics, Inc., Director de The Boston Consulting Group, Inc., Director Comercial de Oncternal Therapeutics, Inc, Director de Operaciones y Vicepresidente Senior de AmpliPhi Biosciences Corp., Jefe de Investigación y Desarrollo de Symyx Technologies, Inc., Vicepresidente Senior de Desarrollo Corporativo de Vical, Inc. y Vicepresidente Senior de Operaciones Especiales, Director General de Inmuno y Oncología de Ignyta, Inc. Igor P. Bilinsky se licenció en el Instituto de Física y Tecnología de Moscú y se doctoró en el Instituto Tecnológico de Massachusetts.
Participaciones conocidas en empresas públicas
Empresa | Fecha | Número de acciones | Valoración | Fecha de valoración |
---|---|---|---|---|
04/03/2024 | 36 641 ( 0.01% ) | 582 958 $ | 29/02/2024 |
Cargos activos de Igor Bilinsky
Empresas | Cargo | Inicio |
---|---|---|
IOVANCE BIOTHERAPEUTICS, INC. | Chief Operating Officer | 15/03/2021 |
Antiguos cargos conocidos de Igor Bilinsky.
Empresas | Cargo | Fin |
---|---|---|
ONCTERNAL THERAPEUTICS, INC. | Corporate Officer/Principal | 01/03/2021 |
AmpliPhi Biosciences Corp.
AmpliPhi Biosciences Corp. BiotechnologyHealth Technology AmpliPhi Biosciences Corp. clinical-stage biotechnology company, which engages in the discovery, development, and commercialization of therapies for antibiotic-resistant infections using bacteriophage-based technology. Its products include AB-SA01 and AB-PA01, which targets staphylococcus aureus and pseudomonas aeruginosa. The company was founded in March 1989 and is headquartered in San Diego, CA. | Chief Operating Officer | 14/01/2019 |
IGNYTA INC | Corporate Officer/Principal | 01/01/2017 |
HALOZYME THERAPEUTICS, INC. | Corporate Officer/Principal | 01/01/2010 |
Androclus Therapeutics, Inc. | Chief Executive Officer | 01/01/2007 |
Formación de Igor Bilinsky.
Massachusetts Institute of Technology | Doctorate Degree |
Moscow Institute of Physics & Technology | Undergraduate Degree |
Experiencias
Funciones ocupadas
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Relaciones
Relaciones de 1er grado
Empresas vinculadas al 1er grado
Hombre
Mujer
Administradores
Ejecutivos
Empresas relacionadas
Empresas cotizadas | 3 |
---|---|
HALOZYME THERAPEUTICS, INC. | Health Technology |
IOVANCE BIOTHERAPEUTICS, INC. | Health Technology |
ONCTERNAL THERAPEUTICS, INC. | Health Technology |
Empresas privadas | 6 |
---|---|
Vical, Inc.
Vical, Inc. Pharmaceuticals: MajorHealth Technology Vical, Inc. engages in the research and development of biopharmaceutical products based on patented DNA delivery technologies for the prevention and treatment of serious and life-threatening diseases. It focuses on the antifungal VL-2397, which treats patients with invasive aspergillosis. Its products include Vaxfectin, a cationic lipid formulation optimized to increase the immune response to vaccines. The company was founded by Howard E. Greene, Jr. Timothy J. Wollaeger, Karl Y. Hostetler, and Douglas D. Richman in April 1987 and is headquartered in San Diego, CA. | Health Technology |
AmpliPhi Biosciences Corp.
AmpliPhi Biosciences Corp. BiotechnologyHealth Technology AmpliPhi Biosciences Corp. clinical-stage biotechnology company, which engages in the discovery, development, and commercialization of therapies for antibiotic-resistant infections using bacteriophage-based technology. Its products include AB-SA01 and AB-PA01, which targets staphylococcus aureus and pseudomonas aeruginosa. The company was founded in March 1989 and is headquartered in San Diego, CA. | Health Technology |
Symyx Technologies, Inc.
Symyx Technologies, Inc. Packaged SoftwareTechnology Services Symyx Technologies, Inc. develops and applies high-throughput experimentation to the discovery of materials for chemical and petrochemical, pharmaceutical development, electronics, consumer goods and automotive customers. The company works together with companies seeking to transform their search for better products and processes through research collaborations and Discovery Tools sales and the license of materials, intellectual property and software. The company was incorporated in February 1999 and is headquartered in Sunnyvale, CA. | Technology Services |
The Boston Consulting Group, Inc.
The Boston Consulting Group, Inc. Miscellaneous Commercial ServicesCommercial Services The Boston Consulting Group, Inc. engages in the provision of management consulting services. It specializes in automotive and mobility; biopharmaceuticals; consumer products; education; oil and gas; power and utilities; engineered products and infrastructure; financial institutions; and health care payers, providers, and services. It offers big data and advanced analytics; change management; client learning and enablement; and corporate development and financial services. The company was founded by Bruce Doolin Henderson in 1963 and is headquartered in Boston, MA. | Commercial Services |
Androclus Therapeutics, Inc. | |
Ignyta, Inc.
Ignyta, Inc. BiotechnologyHealth Technology Ignyta, Inc. operates as a medicine biotechnology company. The firm engages in the discovering, acquiring, developing and commercializing targeted new drugs for cancer patients. The company was founded by Jonathan E. Lim on September 13, 2011 and is headquartered in South San Francisco, CA. | Health Technology |